Researchers at the Samuel Lunenfeld Research Institute have discovered a crucial component of Tankyrase, a protein linked to the bone development disorder cherubism. The study reveals how Tankyrase identifies its substrates, opening new avenues for inhibiting its function in cancer therapy.
Researchers at Mount Sinai Hospital and University of Toronto identified the PTPN22 gene mutation's impact on immune cells, leading to hyper-immune responses and autoimmune disorders. The study's findings will help develop new diagnostic tests and targeted therapies for rheumatoid arthritis and other autoimmune conditions.
Researchers found genetic rearrangements and 'copy number variations' associated with reprogramming adult cells to induced pluripotent stem cells. The study highlights the need for rigorous characterization of generated iPS lines to ensure genomic integrity.
Dr. Nagy's method uses a novel wrapping procedure to deliver specific genes, overcoming major hurdles for personalized stem cell therapies. The breakthrough accelerates stem cell technology and provides a road map for new clinical approaches to regenerative medicine.
Researchers at Mount Sinai Hospital have developed a new technology tool called DyNeMo that analyzes breast cancer tumors to determine the best treatment options. The tool predicts patient recovery with over 80% accuracy and may be used to analyze other types of cancer.
Researchers at Mount Sinai Hospital have developed a new once-weekly treatment for type 2 diabetes that mimics the action of GLP-1, a naturally occurring hormone. The treatment showed significant improvements in glucose control and reduced side effects compared to twice-daily injections.
A study by researchers at the Samuel Lunenfeld Research Institute found that exposure to polycyclic aromatic hydrocarbons (PAHs) prior to pregnancy can reduce the number of eggs in a woman's ovaries, potentially limiting fertility. The compounds are widespread pollutants found in cigarette smoke, car exhaust, and charred foods.
Researchers from Mount Sinai Hospital's Samuel Lunenfeld Research Institute have discovered a genetic 'roadblock' that sensitizes mice to insulin, paving the way for new treatments. The study found that eliminating the glycogen synthase kinase-3 (GSK-3) gene made insulin more effective in regulating blood sugar levels.
Researchers develop computational method to better understand protein networks and their regulation through phosphorylation. This approach aims to target human diseases by identifying aberrant genes in kinase-controlled processes.
Researchers at Samuel Lunenfeld Research Institute have discovered a connection between sugar modifications on proteins and cancer. The study shows how these modifications control protein availability, affecting cell behavior and tumor growth.